CD40-CD40L信号通路在移植免疫中的应用与进展

董红锰; 白纯; 李先亮; 贺强

doi:10.3969/j.issn.1674-7445.2016.04.013

CD40-CD40L信号通路在移植免疫中的应用与进展

doi: 10.3969/j.issn.1674-7445.2016.04.013

100020 首都医科大学附属北京朝阳医院肝胆胰脾外科

基金项目:

国家自然基金面上项目 81571554、81273270、81471590

详细信息

通讯作者:
李先亮，Email：lixianliangbjcy@126.com

贺强，Email： qianghe@medmail.com.cn

中图分类号: R617，R392.4
计量
- 文章访问数: 270
- HTML全文浏览量: 80
- PDF下载量: 17
- 被引次数: 0
出版历程
- 收稿日期: 2016-04-20
- 网络出版日期: 2021-01-19
- 刊出日期: 2016-07-15

摘要

摘要: CD40-CD40L信号通路在特异性免疫中是一条重要的细胞信号传导通路，它参与体液免疫和细胞免疫的调节。动物实验表明抗CD40L单克隆抗体(mAb)阻断CD40与CD40L的结合，从而阻断CD40-CD40L信号的传导，具有抑制器官移植排斥反应的作用。近年来抗CD40LmAb在临床试验中出现的血栓并发症导致其应用受到了质疑。随着人们对CD40-CD40L信号通路的认识不断深入，尤其是新的抗CD40mAb的应用，使得克服与之相关的血栓并发症成为可能，加之其在动物器官移植模型中表现出良好的应用前景，相信这将会进一步推动器官移植免疫耐受及免疫抑制剂方案的发展。本文就CD40-CD40L信号通路在器官移植方面取得的进展进行综述。
- CD40-CD40L /
- 抗CD40L单克隆抗体 /
- 急性排斥反应 /
- 免疫耐受

HTML全文

参考文献(28)

[1]	Pinelli DF, Ford ML. Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance[J]. Immunotherapy, 2015,7(4):399-410. doi: 10.2217/imt.15.1
[2]	Larsen CP, Alexander DZ, Hollenbaugh D, et al. CD40-gp39 interactions play a critical role during allograft rejection. suppression of allograft rejection by blockade of the CD40-gp39 pathway[J]. Transplantation, 1996,61(1):4-9. doi: 10.1097/00007890-199601150-00002
[3]	Coenen JJ, Koenen HJ, van Rijssen E, et al. Tolerizing effects of co-stimulation blockade rest on functional dominance of CD4⁺CD25⁺ regulatory T cells[J]. Transplantation, 2005,79(2):147-156. doi: 10.1097/01.TP.0000147460.93587.87
[4]	Guillonneau C, Hill M, Hubert F, et al. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-γ, and indoleamine 2,3-dioxygenase[J]. J Clin Invest,2007,117(4):1096-1106. doi: 10.1172/JCI28801
[5]	Iwakoshi NN, Mordes JP, Markees TG, et al. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8⁺ T cells and prolonged craft survival in a CTLA4-dependent manner[J]. J Immunol, 2000,164(1):512-521. doi: 10.4049/jimmunol.164.1.512
[6]	Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance[J]. J Clin Invest, 2003,111(12):1887-1895. doi: 10.1172/JCI200317477
[7]	Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition[J]. Nat Rev Immunol, 2013,13(4):227-242. doi: 10.1038/nri3405
[8]	Seah SG, Carrington EM, Ng WC, et al. Unlike CD4⁺ T-cell help, CD28 costimulation is necessary for effective primary CD8⁺ T-cell influenza-specific immunity[J]. Eur J Immunol, 2012,42(7):1744-1754. doi: 10.1002/eji.v42.7
[9]	叶启翔,许吕宏,许威,等. 阻断B7/CD28及CD40/CD154共刺激信号对致敏小鼠免疫功能的影响[J]. 中国实验血液学杂志,2014,22(3):801-806. http://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201403046.htm Ye QX, Xu LH, Xu W, et al. Influence of blocking B7/CD28 and CD40/CD154 co-stimulatory signals on immune function of sensitized mice[J]. J Exp Hematol, 2014,22(3):801-806. http://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201403046.htm
[10]	Badell IR, Russell MC, Cardona K, et al. CTLA4Ig prevents alloantibody formation following nonhuman primate islet transplantation using the CD40-specific antibody 3A8[J]. Am J Transplant,2012,12(7):1918-1923. doi: 10.1111/j.1600-6143.2012.04029.x
[11]	Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo[J]. Nat Immunol, 2002,3(11):1097-1101. doi: 10.1038/ni846
[12]	Guillonneau C, Seveno C, Dugast AS, et al. Anti-CD28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients[J]. J Immunol,2007,179(12):8164-8171. doi: 10.4049/jimmunol.179.12.8164
[13]	Poirier N, Dilek N, Mary C, et al. FR104, an antagonist Anti-CD28 monovalent fab′ antibody, prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate renal allograft[J]. Am J Transplant, 2015,15(1):88-100. doi: 10.1111/ajt.12964
[14]	Guillonneau C, Aubry V, Renaudin K, et al. Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade[J]. Transplantation, 2005,80(4):546-554. doi: 10.1097/01.TP.0000165429.57421.D6
[15]	Dai H, Peng F, Lin M, et al. Anti-OX40L monoclonal antibody prolongs secondary heart allograft survival based on CD40/CD40L and LFA-1/ICAM-1 blockade[J]. Transpl Immunol, 2015,32(2):84-91. doi: 10.1016/j.trim.2015.01.001
[16]	Li T, Ma R, Zhu J, et al. Blockade of the OX40/OX40L pathway and induction of PD-L1 synergistically protects mouse islet allografts from rejection[J]. Chin Med J,2014,127(14):2686-2692. http://cn.bing.com/academic/profile?id=2337155070&encoded=0&v=paper_preview&mkt=zh-cn
[17]	Lee J, Lee EN, Kim EY, et al. 4-1BB promotes long-term survival in skin allografts treated with anti-CD45RB and anti-CD40L monoclonal antibodies[J]. Transplant Proc, 2005,37(1):123-125. doi: 10.1016/j.transproceed.2005.01.016
[18]	Zhang C, Shan J, Lu J, et al. Rapamycin in combination with donor-specific CD4⁺CD25⁺Treg cells amplified in vitro might be realize the immune tolerance in clinical organ transplantation[J]. Cell Immunol, 2010,264(2):111-113. doi: 10.1016/j.cellimm.2010.05.014
[19]	Miroux C, Moralès O, Carpentier A, et al. Inhibitory effects of cyclosporine on human regulatory T cells in vitro[J]. Transplant Proc, 2009,41(8):3371-3374. doi: 10.1016/j.transproceed.2009.08.043
[20]	Bocian K, Borysowski J, Wierzbicki P, et al. Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4⁺CD25⁺ Tregs[J]. Nephrol Dial Transplant, 2010,25(3):710-717. doi: 10.1093/ndt/gfp586
[21]	Pilat N, Klaus C, Schwarz C, et al. Rapamycin and CTLA4Ig synergize to induce stable mixed chimerism without the need for CD40 blockade[J]. Am J Transplant, 2015,15(6):1568-1579. doi: 10.1111/ajt.13154
[22]	杨晓勇,姚庆春,胡小鹏,等. 雷帕霉素体外预处理树突细胞调节Treg/Th17细胞诱导小鼠移植免疫耐受[J].中华医学杂志,2015,95(30):2469-2473. Yang XY, Yao QC, Hu XP, et al. Rapamycin-conditioned dendritic cells induced immune tolerance through the regulation of Treg/Th17 cells in mice[J]. Natl Med J China, 2015,95(30):2469-2473.
[23]	Law CL, Grewal IS. Therapeutic interventions targeting CD40L (CD154) and CD40: The opportunities and challenges[J]. Adv Exp Med Biol, 2009,647:8-36. doi: 10.1007/978-0-387-89520-8
[24]	Pinelli DF, Wagener ME, Liu D, et al. An anti-CD154 domain antibody prolongs graft survival and induces foxp3⁺iTreg in the absence and presence of CTLA-4 Ig[J]. Am J Transplant, 2013,13(11):3021-3030. doi: 10.1111/ajt.12417
[25]	Watanabe M, Yamashita K, Suzuki T, et al. ASKP1240, a fully human anti-CD40 monoclonal antibody, prolongs pancreatic islet allograft survival in nonhuman primates[J]. Am J Transplant, 2013,13(8):1976-1988. doi: 10.1111/ajt.12330
[26]	Oura T, Yamashita K, Suzuki T, et al. Long-Term hepatic allograft acceptance based on CD40 blockade by ASKP1240 in nonhuman primates[J]. Am J Transplant, 2012,12(7):1740-1754. doi: 10.1111/j.1600-6143.2012.04014.x
[27]	Cordoba F, Wieczorek G, Audet M, et al. A novel, blocking, Fc-Silent anti-CD40 monoclonal antibody prolongs nonhuman primate renal allograft survival in the absence of B cell depletion[J]. Am J Transplant, 2015,15(11):2825-2836. doi: 10.1111/ajt.13377
[28]	Ripoll E, Pluvinet R, Torras J, et al. In vivo therapeutic efficacy of intra-renal CD40 silencing in a model of humoral acute rejection[J]. Gene Ther, 2011,18(10):945-952. doi: 10.1038/gt.2011.39